Onconetix Inc (ONCO)vsVertex Pharmaceuticals Inc (VRTX)
ONCO
Onconetix Inc
$3.03
+428.33%
HEALTHCARE · Cap: $964,110
VRTX
Vertex Pharmaceuticals Inc
$454.97
-0.27%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1471784% more annual revenue ($12.00B vs $815,370). VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
ONCO
Avoid30
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ONCO.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -115.5% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ONCO
The strongest argument for ONCO centers on Price/Book, Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : ONCO
The primary concerns for ONCO are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ONCO profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
ONCO carries more volatility with a beta of 3.52 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 30/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Onconetix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Onconetix Inc. is a pioneering biotechnology firm dedicated to transforming cancer care through the advancement of innovative diagnostic and therapeutic solutions. Leveraging its proprietary technology platform, the company focuses on enhancing early detection and personalized treatment strategies across various malignancies, thereby addressing a critical need in oncology. With a robust pipeline that reflects its commitment to addressing the growing demand for effective cancer therapies, Onconetix is well-positioned to make a significant impact on patient outcomes through its cutting-edge research and development initiatives in the rapidly evolving landscape of cancer treatment.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?